Πληροφορίες

Η φωτογραφία μου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com, https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn , ,https://plus.google.com/u/0/+AlexandrosGSfakianakis , https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ , https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA , https://twitter.com/g_orl?lang=el, https://www.instagram.com/alexandrossfakianakis/,

Δημοφιλείς αναρτήσεις

! # Ola via Alexandros G.Sfakianakis on Inoreader

Δευτέρα, 24 Ιουλίου 2017

The K-Ras effector p38p38{gamma}MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR de-phosphorylation [Cell Biology]

Mutations in K-Ras and epidermal growth factor receptor (EGFR) are mutually exclusive, but it is not known how K-Ras activation inactivates EGFR leading to resistance of cancer cells to anti-EGFR therapy. Here, we report that the K-Ras effector p38γMAPK confers intrinsic resistance to small molecular tyrosine kinase inhibitors (TKIs) by concurrently stimulating EGFR gene transcription and protein de-phosphorylation. We found that p38γ increases EGFR transcription by c-Jun mediated promoter-binding and stimulates EGFR de-phosphorylation via activation of protein tyrosine phosphatase H1 (PTPH1). Silencing the p38γ/c-Jun/PTPH1 signaling network increased sensitivities to TKIs in K-Ras mutant cells in which EGFR knockdown inhibited growth. Similar results were obtained with the p38γ-specific pharmacological inhibitor pirfenidone. These results indicate that in K-Ras mutant cancers EGFR activity is regulated by the p38γ/c-Jun/PTPH1 signaling network whose disruption may be a novel strategy to restore the sensitivity to TKIs.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vDGzSE
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου